Cardiovascular Diseases

Moderate Coffee Consumption May Benefit the Cardiovascular System, but High Doses Caffeine Can Be Harmful

Moderate consumption of naturally caffeinated beverages, particularly coffee, is generally associated with a lower risk of several cardiovascular diseases, whereas high doses of caffeine—such as those found in many energy drinks—may increase cardiovascular risk. Caffeine is one of the world’s most widely consumed psychoactive substances, and its cardiovascular effects vary depending on the source of caffeine, the amount consumed, individual characteristics, and whether intake is acute or habitual. Most studies suggest an inverse J-shaped relationship between naturally caffeinated products and blood pressure, with moderate intake linked to more favorable blood pressure levels. Evidence on caffeine and diabetes remains mixed, although regular coffee consumption has consistently been associated with a lower risk of developing type 2 diabetes. Overall, caffeine does not appear to have a clear effect on blood lipid levels, but unfiltered coffee can increase low-density lipoprotein (LDL) cholesterol. Research, primarily involving coffee, has found either no association or a reduced risk of coronary artery disease and heart failure. Randomized trials among habitual coffee drinkers also showed that caffeinated coffee lowers the risk of atrial fibrillation but increases the frequency of premature ventricular contractions. In addition, moderate coffee consumption has been consistently associated with a lower risk of stroke, while evidence on very high caffeine intake, especially from energy drinks, suggests potential cardiovascular harm. Source: https://www.ahajournals.org/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

20 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

22 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.